Weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed/refractory multiple myeloma (MM): A phase I study.
Shaji Kumar
Consultant or Advisory Role - Celgene; Merck
Honoraria - Merck
Research Funding - Celgene; Genzyme; Millennium; Novartis
William Bensinger
Consultant or Advisory Role - Celgene; Millennium; Onyx
Honoraria - Celgene; Millennium; Onyx
Research Funding - Array BioPharma; AstraZeneca; Celgene; Genentech; Millennium; Onyx
Craig B. Reeder
Research Funding - Celgene; Millennium; Novartis
Todd M. Zimmerman
Consultant or Advisory Role - Novartis
Honoraria - Celgene; Millennium
James R. Berenson
Consultant or Advisory Role - Celgene; Medtronic; Millennium; Novartis; Onyx
Honoraria - Celgene; Medtronic; Millennium; Novartis; Onyx
Research Funding - Genentech; Merck
Guohui Liu
Employment or Leadership Position - Millennium
Deborah Berg
Employment or Leadership Position - Millennium
Neeraj Gupta
Employment or Leadership Position - Millennium
Alessandra Di Bacco
Employment or Leadership Position - Millennium
Ai-Min Hui
Employment or Leadership Position - Millennium
Ruben Niesvizky
Consultant or Advisory Role - Celgene; Millennium; Onyx
Research Funding - Celgene; Millennium; Onyx